Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors

The successful uptake of immune checkpoint inhibitors (ICIs) for cancer treatment is illustrated by the increasing number of tumour types and treatment settings for which these treatments have proven efficacy (1 –4). To date, ICIs are standard of care for multiple types of cancer and are used in different treatment settings, i.e., palliative, adjuvant and neoadjuvant (1,5,6). Although ICIs can induce a remarkable durable tumour response, only a subset of patients experience clinical benefit from treatment with ICIs (7).

Source: Cancer Treatment Reviews - November 27, 2023 Category: Cancer & Oncology Authors: Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen Source Type: research